Senescence-initiated Reversal of Drug Resistance: Specific Role of Cathepsin L

Cancer Research

Volumn 64, Issue 5, 2004, Pages 1773-1780

  Zheng, Xin ^a   Chou, Pauline M ^a   Mirkin, Bernard L ^a,b   Rebbaa, Abdelhadi ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CASPASE; CASPASE INHIBITOR; CATHEPSIN B; CATHEPSIN L; CISPLATIN; DOXORUBICIN; PROTEASOME; PROTEIN P21; PROTEINASE INHIBITOR; SMALL INTERFERING RNA; VINBLASTINE; CASP3 PROTEIN, HUMAN; CASPASE 3; CATHEPSIN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; CYSTEINE PROTEINASE;

ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG DISTRIBUTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; RNA INTERFERENCE; SENESCENCE; SIGNAL TRANSDUCTION; ANIMAL; CELL AGING; DRUG ANTAGONISM; DRUG RESISTANCE; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CASPASE 3; CASPASES; CATHEPSINS; CELL AGING; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTEINE ENDOPEPTIDASES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RNA, SMALL INTERFERING;

EID: 1642269770     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-0820     Document Type: Article

References (37)

1. Kroemer, G., and Reed, J. C. Mitochondrial control of cell death. Nat. Med., 6: 513-519, 2000.
2. Reed, J. C. Apoptosis-targeted therapies for cancer. Cancer Cell, 3: 17-22, 2003.
3. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
4. Friesen, C., Fulda, S., and Debatin, K. M. Cytotoxic drugs and the CD95 pathway. Leukemia (Baltimore), 13: 1854-1858, 1999.
5. Debatin, K. M., Poncet, D., and Kroemer, G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene, 21: 8786-8803, 2002.
6. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer, 2: 420-430, 2002.
7. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
8. Brown, J. M., and Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res., 59: 1391-1399, 1999.
9. Borst, P., Borst, J., and Smets, L. A. Does resistance to apoptosis affect clinical response to antitumor drugs? Drug Resist. Update, 4: 129-131, 2001.
10. Roninson, I. B., Broude, E. V., and Chang, B. D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Update, 4: 303-313, 2001.
11. Roninson, I. B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett., 179: 1-14, 2002.
12. Hartmann, A., Troadec, J. D., Hunot, S., Kikly, K., Faucheux, B. A., Mouatt-Prigent, A., Ruberg, M., Agid, Y., and Hirsch, E. C. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J. Neurosci., 21: 2247-2255, 2001.
13. Kim, S. O., and Han, J. Pan-caspase inhibitor zVAD enhances cell death in RAW246.7 macrophages. J. Endotoxin Res., 7: 292-296, 2001.
14. Luschen, S., Ussat, S., Scherer, G., Kabelitz, D., and Adam-Klages, S. Sensitization to death receptor cytotoxicity by inhibition of fas-associated death domain protein (FADD)/caspase signaling. Requirement of cell cycle progression. J. Biol. Chem., 275: 24670-24678, 2000.
15. Martinsson, P., Liminga, G., Nygren, P., and Larsson, R. Characteristics of etoposide-induced apoptotic cell death in the U-937 human lymphoma cell line. Anticancer Drugs, 12: 699-705, 2001.
16. Yaginuma, H., Shiraiwa, N., Shimada, T., Nishiyama, K., Hong, J., Wang, S., Momoi, T., Uchiyama, Y., and Oppenheim, R. W. Caspase activity is involved in, but is dispensable for, early motoneuron death in the chick embryo cervical spinal cord. Mol. Cell Neurosci., 18: 168-182, 2001.
17. Coelho, D., Holl, V., Weltin, D., Lacornerie, T., Magnenet, P., Dufour, P., and Bischoff, P. Caspase-3-like activity determines the type of cell death following ionizing radiation in MOLT-4 human leukaemia cells. Br. J. Cancer, 83: 642-649, 2000.
18. Rebbaa, A., Zheng, X., Chou, P., and Mirkin, B. L. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene. 22: 2805-2811, 2003.
19. Rebbaa, A., Chou, P. M., and Mirkin, B. L. Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol. Med., 7: 393-400, 2001.
20. Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., and Pereira-Smith, O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA, 92: 9363-9367, 1995.
21. Chang, B. D., Swift, M. E., Shen, M., Fang, J., Broude, E. V., and Roninson, I. B. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc. Natl. Acad. Sci. USA, 99: 389-394, 2002.
22. Miller, R. J., and Wilson, S. M. Neurological disease: UPS stops delivering! Trends Pharmacol. Sci., 24: 18-23, 2003.
23. Turk, V., Turk, B., and Turk, D. Lysosomal cysteine proteases: facts and opportunities. EMBO J., 20: 4629-4633, 2001.
24. Adams, J. Proteasome inhibitors as new anticancer drugs. Curr. Opin. Oncol., 14: 628-634, 2002.
25. McNaught, K. S., Olanow, C. W., Halliwell, B., Isacson, O., and Jenner, P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci., 2: 589-594, 2001.
26. Isahara, K., Ohsawa, Y., Kanamori, S., Shibata, M., Waguri, S., Sato, N., Gotow, T., Watanabe, T., Momoi, T., Urase, K., Kominami, E., and Uchiyama, Y. Regulation of a novel pathway for cell death by lysosomal aspartic and cysteine proteinases. Neuroscience, 91: 233-249, 1999.
27. Hishita, T., Tada-Oikawa, S., Tohyama, K., Miura, Y., Nishihara, T., Tohyama, Y., Yoshida, Y., Uchiyama, T., and Kawanishi, S. Caspase-3 activation by lysosomal enzymes in cytochrome c-independent apoptosis in myelodysplastic syndrome-derived cell line P39. Cancer Res., 61: 2878-2884, 2001.
28. Stoka, V., Turk, B., Schendel, S. L., Kim, T. H., Cirman, T., Snipas, S. J., Ellerby, L. M., Bredesen, D., Freeze, H., Abrahamson, M., Bromme, D., Krajewski, S., Reed, J. C., Yin, X. M., Turk, V., and Salvesen, G. S. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J. Biol. Chem., 276: 3149-3157, 2001.
29. Guay, J., Falgueyret, J. P., Ducret, A., Percival, M. D., and Mancini, J. A. Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides. Eur. J. Biochem., 267: 6311-6318, 2000.
30. Jin, Y. H., Yoo, K. J., Lee, Y. H., and Lee, S. K. Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells. J. Biol. Chem., 275: 30256-30263, 2000.
31. Hurwitz, S. J., Terashima, M., Mizunuma, N., and Slapak, C. A. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes. Blood, 89: 3745-3754, 1997.
32. Stypmann, J., Glaser, K., Roth, W., Tobin, D. J., Petermann, I., Matthias, R., Monnig, G., Haverkamp, W., Breithardt, G., Schmahl, W., Peters, C., and Reinheckel, T. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc. Natl. Acad. Sci. USA, 99: 6234-6239, 2002.
33. Felbor, U., Kessler, B., Mothes, W., Goebel, H. H., Ploegh, H. L., Bronson, R. T., and Olsen, B. R. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl. Acad. Sci. USA, 99: 7883-7888, 2002.
34. Roth, W., Deussing, J., Botchkarev, V. A., Pauly-Evers, M., Saftig, P., Hafner, A., Schmidt, P., Schmahl, W., Scherer, J., Anton-Lamprecht, I., Von Figura, K., Paus, R., and Peters, C. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and perturbation of hair follicle cycling. FASEB J., 14: 2075-2086, 2000.
35. Benavides, F., Starost, M. F., Flores, M., Gimenez-Conti, I. B., Guenet, J. L., and Conti, C. J. Impaired hair follicle morphogenesis and cycling with abnormal epidermal differentiation in nackt mice, a cathepsin L-deficient mutation. Am. J. Pathol., 161: 693-703, 2002.
36. Hashmi, S., Britton, C., Liu, J., Guiliano, D. B., Oksov, Y., and Lustigman, S. Cathepsin L is essential for embryogenesis and development of Caenorhabditis elegans. J. Biol. Chem., 277: 3477-3486, 2002.
37. Wang, E., Lee, M. D., and Dunn, K. W. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. J. Cell Physiol., 184: 263-274, 2000.